Post by Algaurizin

BREAKING: The FDA just cleared three first-in-class therapies in a single week. Including: ✅ The first drug to finally crack the PI3K "white whale" in breast cancer ✅ The first cancer therapy via wearable on-body injector ✅ The first oral PCSK9 pill for cholesterol This is life sciences history in motion. Why this matters: For patients: Options where none existed before. REVTORPYK alone unlocks treatment for ~60% of HR+/HER2- breast cancers previously excluded from PI3K-targeted therapy. For investors: Biopharma M&A crossed $96B in H1 2026. iShares NASDAQ Biotechnology Index (ETF) Index up 56% YoY. The deal engine isn't slowing. For the field: Novel mechanisms + novel delivery + novel regulatory frameworks, all approved simultaneously. That's not coincidence, it's a signal. What leaders are saying: "Revtorpyk addressed this 20-year challenge." — Brian Sullivan, CEO, Celcuity "This is what patient-centered innovation looks like in practice." — John Forni, UK Medical Lead, Sanofi "An effective new treatment option for a population with limited alternatives." — Dr. Sara Hurvitz, Professor, FRED HUTCHINSON CANCER RESEARCH My take: The drug is the molecule. The delivery is the experience. The framework is the future. When all three move at once, you don't have a news cycle. You have an inflection point. Your turn, what stands out to you? → REVTORPYK, rewriting 20 years of oncology dogma → Sarclisa Escena, shifting cancer care from clinic to living room → CRISPR framework, making personalized medicine commercially viable → M&A wave, biotech is back, and back big I'm leaning toward the CRISPR framework. Regulation is the rate-limiting step. You can have the best drug and the slickest device, but if the FDA can't approve it for your mutation, it doesn't matter. The "plausible mechanism" pathway changes that equation entirely. Here's what stays with me: Behind every headline is: • A family waiting for an oncologist call • A patient dreading another infusion chair • A parent whose child might see bespoke gene therapy in months, not decades If you know someone who needs to hear the pipeline is delivering, not promising, delivering, share this with them. One more thing: Repost → Signal to your network that you're tracking shifts before they become consensus. DM someone → That colleague, investor, or clinician who needs to see $96B in deals to believe the tide has turned. You're not just sharing insight. You're amplifying hope with evidence. #REVTORPYK #Lipfendra #Sarclisa #FDA